Publications
| Title | Abstract | Year(sorted ascending) Filter | PMID Filter |
|---|
| chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates nf-kappab and induces tissue factor and pai-1 expression: a potential link to accelerated arteriosclerosis. | recent reports link c. pneumoniae infection of arteriosclerotic lesions to the precipitation of acute coronary syndromes, which also feature tissue factor and plasminogen activator inhibitor 1 (pai-1) overexpression. we investigated whether or not c. pneumoniae can induce thrombogenicity by upregulation of procoagulant proteins. | 1999 | 10500035 |
| safety and effect on anti-chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease. | a pilot study of azithromycin treatment following percutaneous coronary revascularization procedures was performed to assess safety and the effect of azithromycin treatment on anti-chlamydia pneumoniae antibody titres. patients were randomized to a 1 month course of azithromycin (total dose of 8.0 g) or placebo. safety and compliance were assessed at 2 and 4 weeks and serological testing was performed on samples obtained at enrolment and at 6 months post-enrolment. azithromycin was well tolerate ... | 1999 | 10511413 |
| iron and the role of chlamydia pneumoniae in heart disease. | 1999 | 10511533 | |
| the prevalence of chlamydia pneumoniae antibodies in thai patients with coronary artery disease. | blood samples were obtained from 243 consecutive coronary artery disease (cad) patients (177 male, 66 female) aged 35-78 years (mean, 61 years) admitted for coronary angiography because of suspected coronary heart disease, and from 115 blood donors (91 male, 24 female) aged 25-60 years (mean, 47 years). of the 243 cad patients, 179 (74%) were positive by an elisa method for chlamydia pneumoniae antibodies igg and 132 (54%) were positive for c. pneumoniae iga. among the 115 blood donors, 80 (70%) ... | 1999 | 10511787 |
| chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. results from a nested case-control study in northern sweden. | an association between high lipoprotein(a) [lp(a)] levels and positive chlamydia pneumoniae igg titers in coronary artery disease has been described. the possibility of predicting ischemic stroke by measurements of plasma lp(a) and c pneumoniae antibodies was investigated. | 1999 | 10512900 |
| lack of association between seropositivity to chlamydia pneumoniae and carotid atherosclerosis. | since the chlamydia pneumoniae (c. pneumoniae)-specific antibody was shown to be associated with acute myocardial infarction and chronic coronary heart disease, the role of c. pneumoniae in the etiology of cardiovascular disease has been studied by a number of groups. we investigated the association between the c. pneumoniae-specific antibody, measured by microimmunofluorescence, risk factors for cardiovascular disease, and atherosclerosis in a randomly selected urban population. overall, immuno ... | 1999 | 10513782 |
| lower prevalence of chlamydia pneumoniae dna compared with chlamydia trachomatis dna in synovial tissue of arthritis patients. | to assess the presence of chlamydia pneumoniae dna in the joints of patients with reactive arthritis (rea) and other arthritides. | 1999 | 10513803 |
| chlamydia pneumoniae may be associated with lung cancer. preliminary report on a seroepidemiological study. | material from 117 consecutive patients with lung cancer was investigated with respect to serological markers for chronic chlamydia pneumoniae infection. specific c. pneumoniae iga antibodies were found significantly more often in patients with lung cancer than in control groups with coronary heart disease and in healthy controls, even after adjustment for smoking. the results suggest that chronic c. pneumoniae infection is common in patients with lung cancer. | 1999 | 10519317 |
| demonstration of chlamydia pneumoniae in tissue by immunohistochemistry. | chronic chlamydia pneumoniae infection may be difficult to diagnose using routine methods such as culture, antigen detection, serology and polymerase chain reaction (pcr). we describe a method for the immunohistochemical staining of tissue biopsies using a c. pneumoniae-specific monoclonal antibody and a streptavidin/biotin technique. this method provides specific identification of the organism and reveals its actual location in tissues which may or may not be inflamed. host cells containing c. ... | 1999 | 10519326 |
| quantitation of bacterial adherence by image analysis. | in studies of the adherence of pathogenic bacteria to host eukaryotic cells in vitro, the counting of the bacteria is often challenging, especially if many experiments are involved. we developed a method to use digital imaging and computer-aided recognition for the quantitation of bacteria attached to cultured cells. we employed an immunocytochemical method to stain the bacteria and leave the hosts cells relatively unstained. we describe this method for use with five species of bacteria, strepto ... | 1999 | 10520581 |
| baseline igg antibody titers to chlamydia pneumoniae, helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. | results of cross-sectional and retrospective studies have suggested that chronic infection may be a risk factor for cardiovascular disease. however, prospective data evaluating the relation between baseline antibody titers against various plausible agents and risk for cardiovascular disease are sparse, particularly among women. | 1999 | 10523217 |
| chlamydia pneumoniae infection in children with persistent cough. | 1999 | 10523255 | |
| [infections and cardiovascular disease]. | epidemiological studies indicate that respiratory tract and dental infections increase the risk of atherosclerotic cardiovascular disease. several microorganisms have been claimed as clinically important, especially chlamydia pneumoniae (cp) and cytomegalovirus (cmv), cp is frequently isolated from atherosclerotic plaques, and treatment with macrolide antibiotics may have a beneficial effect on the course of ischaemic heart disease. cmv seems to play a role in the development of coronary stenosi ... | 1999 | 10523948 |
| [chlamydia pneumoniae and atherosclerosis--the hen, the egg or five feathers?]. | 1999 | 10523951 | |
| polymerase chain reaction assay for detecting chlamydia pneumoniae in middle ear fluid of children with otitis media with effusion. | 1999 | 10530596 | |
| a multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. | to compare the efficacies of 10-day regimens of grepafloxacin (gfx) (raxar or vaxar; glaxo wellcome; greenford, uk), 600 qd, and clarithromycin (cla) (klacid, biaxin, or klaracid; abbott laboratories; chicago, il), 500 mg bid, in patients with community-acquired pneumonia (cap), on the basis of clinical response, including radiographic evidence, and bacteriologic efficacy. | 1999 | 10531162 |
| de novo induction of atherosclerosis by chlamydia pneumoniae in a rabbit model. | chlamydia pneumoniae, a bacterial respiratory tract pathogen, has been associated with atherosclerosis in humans. c. pneumoniae infection of the respiratory tracts of rabbits fed a noncholesterol diet induced changes of atherosclerosis of the aorta in 6 (26.1%) of 23 animals after a single inoculum at 3 months. multiple inocula given three times within 6 weeks resulted in grade iii atherosclerosis in 8 (34.8%) of 23 rabbits, with an additional 5 (21. 7%) showing increased myxoid changes in the i ... | 1999 | 10531266 |
| chlamydia trachomatis (mouse pneumonitis strain) induces cardiovascular pathology following respiratory tract infection. | chlamydia, especially chlamydia pneumoniae, infection is closely associated with human cardiovascular diseases. thus far, however, few experimental studies have been carried out to investigate whether natural c. trachomatis infection can induce cardiovascular pathological changes. in this article, we report that pulmonary infection with c. trachomatis mouse pneumonitis strain (mopn) can induce myocardial and perivascular inflammation and fibrosis in c57bl/6 mice. the pulmonary mopn infection app ... | 1999 | 10531278 |
| [clinical analysis of pneumonia in the elderly in a community hospital--comparison of community-acquired pneumonia and nosocomial pneumonia]. | we experienced 530 elderly cases with pneumonia among 930 patients with pneumonia in kawasaki medical school kawasaki hospital between april 1986 and september 1998. clinical analysis of all these patients and a comparison of one group consisting of 418 patients with community-acquired pneumonia and another group composed of 112 patients with nosocomial pneumonia were performed. in all of the elderly patients with pneumonia, respiratory symptoms and inflammatory findings were less frequent, but ... | 1999 | 10535263 |
| c-reactive protein and coronary disease. | 1999 | 10539837 | |
| role of infections in atherosclerosis. | a growing amount of epidemiologic, experimental, and clinical evidence has linked infection as a risk factor to variousatherosclerotic diseases including acute myocardial infarction and cerebral infarction. bacteremic infections with and without endocarditis carry a high risk for both stroke and acute myocardial infarction. during the last decade, chronic bacterial infections such as chlamydia pneumoniae and dental infections have been associated as risk factors for various atherosclerotic disea ... | 1999 | 10539842 |
| coronary heart disease, helicobacter pylori, dental disease, chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies. | 1999 | 10539843 | |
| molecular mediators of arterial inflammation: a role for microbial products? | 1999 | 10539846 | |
| chlamydia pneumoniae and atherosclerosis: links to the disease process. | chlamydia pneumoniae is an obligate intracellular prokaryotic human pathogen responsible for a significant portion of atypical pneumonia and associated with a variety of chronic sequelae, the most significant of which is atherosclerosis. the organism is endowed with several attributes that may contribute to the development of atherosclerotic lesions or promote tissue damage at the site of an existing lesion. two key events that are directly involved in the atherogenic process include the develop ... | 1999 | 10539855 |
| molecular biology of chlamydia pneumoniae surface proteins and their role in immunopathogenicity. | the association of chlamydia pneumoniae with the development of atherosclerosis is based on serology and on detection of c pneumoniae-specific dna by polymerase chain reaction in the atheromas. | 1999 | 10539856 |
| pathologic manifestation of chlamydial infection. | 1999 | 10539857 | |
| epidemiology of chlamydia pneumoniae in atherosclerosis. | chlamydia pneumoniae is a common, ubiquitous respiratory tract agent causing, apart from upper respiratory tract infections, approximately 10% of all pneumonias worldwide. antibody prevalence starts to rise early in life in the developing countries, but in industrialized countries they only begin to rise when the children start school. in early adulthood, antibody prevalence reaches approximately 50%, with men having greater prevalence than women. this prevalence rises toward old age. the pitfal ... | 1999 | 10539858 |
| interaction of chlamydia pneumoniae infection with other risk factors of atherosclerosis. | seroepidemiologic studies have provided information on the interaction of chlamydia pneumoniae with other known risk factors of coronary heart disease. c pneumoniae infection appears to be more common in smokers than in nonsmokers, suggesting that smoking predisposes to the development of chronic c pneumoniae infection. | 1999 | 10539859 |
| in vitro infection and pathogenesis of chlamydia pneumoniae in endovascular cells. | the strength of the epidemiologic and clinical associations of chlamydia pneumoniae with atherosclerosis can be increased by the demonstration that c pneumoniae can initiate and sustain growth in human vascular cells as well as in animal models. to investigate the biological basis for the dissemination and proliferation of this organism in vascular cells, the in vitro growth of c pneumoniae was studied in 2 macrophage cell lines, peripheral blood monocyte (pbmc)-derived macrophages, human bronch ... | 1999 | 10539860 |
| value of animal models for chlamydia pneumoniae-related atherosclerosis. | chlamydia pneumoniae is strongly implicated in the pathogenesis of atherosclerosis in human beings. animal models are important to help establish causality, to understand the mechanism of infection induced atherogenesis, to examine interaction of other factors or variables, to explore treatment regimens and their efficacy, and to help develop a vaccine for prevention. to date, the rabbit model is the only animal model shown to develop de novo atherosclerotic changes with c pneumoniae infection. ... | 1999 | 10539861 |
| animal models of chlamydia and atherosclerosis. | 1999 | 10539862 | |
| mouse models of chlamydia pneumoniae infection and atherosclerosis. | 1999 | 10539863 | |
| multiple infections in carotid atherosclerotic plaques. | chlamydia pneumoniae, cytomegalovirus, herpes simplex virus, and recently, periodontal disease, have been associated with human atherosclerosis. porphyromonas gingivalis and streptococcus sanguis are major pathogens associated with periodontitis, a common chronic inflammatory condition in adults. investigators have found that these infectious agents may influence vascular cell functions by inducing thrombus formation, vascular cell proliferation, apoptosis, and cell death. | 1999 | 10539867 |
| emerging role of antibiotics in atherosclerosis. | it has been shown that plaque composition changes significantly in the setting of acute events, macrophages and t cells being the predominant pattern at the immediate site of fissure or erosion. there appears to be a relation between physical blood stream factors, plaque morphology, and the distribution of inflammatory cells. furthermore, there is cumulative evidence for the presence of intracellular pathogens in the arterial wall, namely chlamydia pneumoniae and cytomegalovirus, which affect en ... | 1999 | 10539868 |
| chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease. | 1999 | 10539869 | |
| wizard and the design of trials for secondary prevention of atherosclerosis with antibiotics. | clinical trials to assess the merit of antibiotic intervention in the treatment of ischemic cardiovascular disease are now underway, spurred on by an association between chlamydia pneumoniae and atherogenesis noted in epidemiologic investigations, histopathologic studies, and results from various animal models. the design of such clinical trials must take into account a number of issues: the primary event as strictly defined by objective criteria, the event rate in the chosen population, the pot ... | 1999 | 10539870 |
| secondary prevention trials for coronary artery disease with antibiotic treatment for chlamydia pneumoniae: design issues. | 1999 | 10539871 | |
| fulfillment of koch's postulates and the causes of atherosclerosis. | 1999 | 10539872 | |
| how to design studies to confirm a link between bacterial infection and atherosclerosis. | 1999 | 10539873 | |
| design of future intervention studies for chlamydia pneumoniae in atherosclerosis. | 1999 | 10539875 | |
| conclusions. | 1999 | 10539877 | |
| chlamydia pneumoniae, asthma, and copd: what is the evidence? | reading this article will familiarize the reader with (1) the unique chlamydial intracellular life cycle and the propensity for human chlamydial infections to become persistent and to result in immunopathologic (inflammatory) damage in target organs and (2) current evidence linking chlamydia pneumoniae (cpn) infection to obstructive lung diseases (asthma and chronic obstructive pulmonary disease, copd). potential therapeutic implications of the cpn-asthma association are also discussed. | 1999 | 10541419 |
| in vitro activities of gemifloxacin (sb 265805, lb20304) against recent clinical isolates of chlamydia pneumoniae. | we compared the in vitro activity of gemifloxacin, a new quinolone antibiotic, to the activities of levofloxacin, moxifloxacin, trovafloxacin, erythromycin, and doxycycline against 20 isolates of chlamydia pneumoniae. gemifloxacin was the most active quinolone tested, with a mic at which 90% of the isolates are inhibited and a minimal bactericidal concentration at which 90% of strains tested are killed of 0.25 microg/ml, but this activity was less than those of doxycycline and erythromycin. | 1999 | 10543770 |
| analysis of the humoral immune response to chlamydia pneumoniae by immunoblotting and immunoprecipitation. | chlamydia pneumoniae is a widely spread agent of respiratory tract infections in humans. a reliable serodiagnosis of the disease is hampered by the poor knowledge about immunodominant antigens in c. pneumoniae infections. we applied a novel strategy to identify immunogenic proteins of c. pneumoniae tw183 combining metabolic radiolabeling of de novo-synthesized chlamydial antigens with immunoprecipitation. by this technique c. pneumoniae antigens of approximately 160, 97 to 99, 60 to 62, 40, 27, ... | 1999 | 10548570 |
| can an antibiotic (macrolide) prevent chlamydia pneumoniae-induced atherosclerosis in a rabbit model? | there is increasing data implicating chlamydia pneumoniae in the pathogenesis of atherosclerosis, and antibiotics may theoretically be useful to prevent secondary vascular complications. three groups of new zealand white specific-pathogen-free rabbits, fed cholesterol-free chow, were inoculated via the nasopharynx on three occasions, 2 weeks apart, with c. pneumoniae. group i (n = 23) rabbits were untreated; group ii (n = 24) rabbits were treated with azithromycin at 30 mg/kg of body weight dail ... | 1999 | 10548582 |
| sézary t-cell activating factor is a chlamydia pneumoniae-associated protein. | we previously identified a protein that was stimulatory for malignant sézary t cells, termed sézary t-cell activating factor (saf). however, the identity of this protein has not been fully elucidated, nor has it's role been determined in the pathogenesis of cutaneous t-cell lymphoma (ctcl). the basis for epidermotropism and proliferation of malignant cells in the skin of patients with ctcl is unknown. using a monoclonal antibody inhibitory for saf activity, we demonstrated that saf is present in ... | 1999 | 10548583 |
| chlamydia pneumoniae eradication from carotid plaques. results of an open, randomised treatment study. | to determine the effect of specific antibiotic treatment with roxithromycin in the eradication of chlamydia pneumoniae from carotid artery plaques. | 1999 | 10550273 |
| circulating chlamydia pneumoniae dna as a predictor of coronary artery disease. | to determine whether current vascular chlamydia pneumoniae (cpn) infection as diagnosed by circulating cpn dna is more common in subjects with coronary artery disease (cad). | 1999 | 10551689 |
| chlamydia pneumoniae infection and coronary artery disease. | 1999 | 10551690 | |
| activity of quinolones against chlamydia pneumoniae. | quinolones are currently being used as empirical therapy for the treatment of community-acquired pneumonia and other respiratory infections as they cover a broad range of conventional bacterial and 'atypical' pathogens, including chlamydia pneumoniae. c. pneumoniae has been associated with 10 to 20% of community-acquired pneumonia in adults and recently has been implicated as being associated with several nonrespiratory conditions, including atherosclerosis. however, data on the treatment of eve ... | 1999 | 10553711 |
| the possible role of infections in acute myocardial infarction. | cardiovascular diseases, particularly coronary heart disease (chd) and myocardial infarction (mi), are among the leading causes for morbidity and mortality in industrialized countries [2, 77]. during the past decades, various clinical or lifestyle risk factors for myocardial infarction such as hyperlipidemia, hypertension, obesity, lack of physical exercise and smoking have been identified. however, it is also recognized that these well-documented risk factors do not sufficiently account for all ... | 1999 | 10554674 |
| enhancement of antibody responses by dna immunization using expression vectors mediating efficient antigen secretion. | the immune responses elicited in mice, after intradermal (i.d.) immunization with plasmids encoding secreted or intracellular forms of hiv-1 nef, hiv-1 tat or c. pneumoniae omp2 proteins, respectively, were compared. to mediate secretion of these proteins the genes were fused to a heterologous signal sequence from murine heavy chain igg. the nef- and omp2-specific antibody responses were dramatically increased when mice were inoculated with the plasmid encoding the secreted form of these protein ... | 1999 | 10556549 |
| chlamydia pneumoniae dna detection in peripheral blood mononuclear cells is predictive of vascular infection. | abdominal aortic aneurysm tissue and peripheral blood mononuclear cells (pbmc) of 41 consecutive subjects undergoing abdominal aortic aneurysm surgery were analyzed by polymerase chain reaction (pcr) for the presence of chlamydia pneumoniae, mycoplasma pneumoniae, and helicobacter pylori dna. twenty patients (49%) were positive for c. pneumoniae dna-16 (39%) in both pbmc and aneurysm tissue, 3 (7.3%) in pbmc only, and 1 (2.4%) in the artery specimen only. previous exposure to c. pneumoniae was c ... | 1999 | 10558974 |
| chlamydia pneumoniae in abdominal aortic aneurysms: abundance of membrane components in the absence of heat shock protein 60 and dna. | in this article, we describe the results of a comparative study for the detection of chlamydia pneumoniae in abdominal aortic aneurysm specimens of 19 patients through the use of immunocytochemistry (icc), in situ hybridization (ish), and polymerase chain reaction (pcr), along with the detection of cytomegalovirus (cmv) and herpes simplex virus (hsv) by icc and pcr. c pneumoniae-specific membrane protein was detected in specimens of all 19 (100%; 95% confidence interval [ci] 82% to 100%) and of ... | 1999 | 10559011 |
| chlamydia pneumoniae and atherosclerosis. | 1999 | 10560368 | |
| [can or should acute asthma exacerbations be treated with macrolides?]. | 1999 | 10562668 | |
| failure to detect chlamydia pneumoniae in brain tissues of alzheimer's disease. | 1999 | 10563652 | |
| molecular diagnosis of chlamydia pneumoniae infection. | 1999 | 10565886 | |
| [chlamydiae--still new surprises]. | a review on participation of chlamydiae in the origin of the hiv-infection, carcinoma and atherosclerosis. the antibodies against the newly discovered pgp3 protein of c. trachomatis were found in 83-87% of the seropositive hiv patients. the participation of c. trachomatis in the etiology of cervical and ovarian carcinoma has been discussed in a number of articles. simultaneous examinations along different lines allow the hypothesis, that c. trachomatis acts as a cofactor in the development of ov ... | 1999 | 10566217 |
| the role of chlamydia in coronary heart disease-fact or fiction? | 1999 | 10570071 | |
| improvement in lipid and haemostasis patterns after helicobacter pylori infection eradication in type 1 diabetic patients. | helicobacter pylori has been implicated in the cardiovascular risk of diabetic patients. the aim of our study was to investigate whether the helicobacter pylori infection plays a role in the lipid and haemostasis patterns of type 1 diabetic patients. twenty nine patients with type 1 diabetes mellitus and h. pylori infection were enrolled (chlamydia pneumoniae negative). the h. pylori infection status was assessed by serology and urease breath test. in all patients levels of total cholesterol, tr ... | 1999 | 10578022 |
| multiplex pcr for rapid and differential diagnosis of mycoplasma pneumoniae and chlamydia pneumoniae in respiratory infections. | a duplex polymerase chain reaction (pcr) was developed for the simultaneous detection of chlamydia pneumoniae and mycoplasma pneumoniae. a study of 163 respiratory specimens from in-patients of the "centre hospitalier et universitaire de nancy" showed the good sensitivity of this duplex pcr allowing the detection of c. pneumoniae and m. pneumoniae from 8 and 13 patients, respectively, whereas the culture was negative for c. pneumoniae for all the samples and positive for m. pneumoniae only in 9 ... | 1999 | 10579089 |
| [association between chlamydial infection and coronary artery disease]. | recent epidemiological studies have demonstrated the association between chlamydia pneumoniae infection and coronary atherosclerosis. however, the relationship is less clear in the japanese population. serum iga and igg antibodies to chlamydia-specific lipopolysaccharide were measured by enzyme-linked immunosorbent assay in 152 consecutive patients(112 males, 40 females, mean age 57 years)who underwent coronary angiography. patients(n = 123)with coronary artery disease(cad)were defined as having ... | 1999 | 10579134 |
| computational analysis of the polymorphic membrane protein superfamily of chlamydia trachomatis and chlamydia pneumoniae. | whole sequence genome analysis is invaluable in providing complete profiles of related proteins and gene families. the genome sequences of the obligate intracellular bacteria chlamydia trachomatis and chlamydia pneumoniae both encode proteins with similarity to several 90-kda chlamydia psittaci proteins. these proteins are members of a large superfamily, c. trachomatis with 9 members and c. pneumoniae with 21 members. all polymorphic membrane protein (pmp) are heterogeneous, both in amino acid s ... | 1999 | 10587946 |
| in-vitro activity of gatifloxacin against chlamydia trachomatis and chlamydia pneumoniae. | we compared the activity of gatifloxacin, a new quinolone, ofloxacin and erythromycin against five isolates of chlamydia trachomatis and 20 isolates of chlamydia pneumoniae, including tw183 and clinical isolates from the usa and japan. testing was done in cycloheximide-treated hep-2 cells. gatifloxacin was slightly less active against c. trachomatis and slightly more active against c. pneumoniae than ofloxacin, with mics at which 90% of the isolates had no inclusions and minimal chlamydicidal co ... | 1999 | 10588319 |
| concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. | the concentrations of moxifloxacin achieved after a single 400 mg dose were measured in serum, epithelial lining fluid (elf), alveolar macrophages (am) and bronchial mucosa (bm). concentrations were determined using a microbiological assay. nineteen patients undergoing fibre-optic bronchoscopy were studied. mean serum, elf, am and bm concentrations at 2.2, 12 and 24 h were as follows: 2.2 h: 3.2 mg/l, 20.7 mg/l, 56.7 mg/l, 5.4 mg/kg; 12 h: 1.1 mg/l, 5.9 mg/l, 54.1 mg/l, 2.0 mg/kg; 24 h: 0.5 mg/l ... | 1999 | 10590288 |
| [respiratory tract infections triggering bronchial asthma attacks--with special reference to the involvement of chlamydia pneumoniae]. | 1999 | 10590540 | |
| antibiotic use and risk of myocardial infarction. | 1999 | 10591378 | |
| chlamydia pneumoniae and atherosclerosis. | 1999 | 10591391 | |
| relation of c pneumoniae antibodies to ischaemic heart disease. why were samples weakly positive for igg antibodies not tested for iga antibodies? | 1999 | 10591734 | |
| comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against chlamydia spp. | the in-vitro activity of moxifloxacin, a new 8-methoxyquinolone, was compared with minocycline and azithromycin against 40 strains of chlamydia trachomatis, chlamydia pneumoniae and chlamydia psittaci. both the mic and the mbc of moxifloxacin ranged from 0.03 to 0.125 mg/l. mics of minocycline ranged from 0.015 to 0.06 mg/l and mbcs between 0.03 and 0.25 mg/l. mics of azithromycin ranged from 0.03 to 0.125 mg/l and the mbcs between 0.06 and 0.5 mg/l. mbc values of moxifloxacin were the same as m ... | 1999 | 10404322 |
| association of cervical artery dissection with recent infection. | cervical artery dissection (cad) is an important cause of ischemic stroke in younger patients. however, its cause is insufficiently understood. | 1999 | 10404987 |
| association of seropositivity for chlamydia pneumoniae and coronary artery disease in heterozygous familial hypercholesterolaemia. | in patients with familial hypercholesterolaemia heterozygous for the north karelia (finland) mutation, the presence of unequivocal coronary heart disease was significantly associated with high titres of igg and iga antibodies to chlamydia pneumoniae. | 1999 | 10406370 |
| chlamydia pneumoniae infection and incident coronary heart disease: the atherosclerosis risk in communities study. | pathologic findings and cross-sectional epidemiologic studies suggest that past infection with chlamydia pneumoniae is associated with clinical and subclinical atherosclerotic disease, although evidence from prospective studies is still scarce. the association between chronic infection by c. pneumoniae and incident coronary heart disease (chd) was investigated in a case-cohort study conducted among participants in the atherosclerosis risk in communities study who were free of chd at the baseline ... | 1999 | 10412959 |
| how useful is the chlamydia micro-immunofluorescence (mif) test for the gynaecologist? | three patients with a chlamydial respiratory tract infection showed significant titre rises for the three chlamydial micro-immunofluorescence tests, performed with chlamydia pneumoniae, c. psittaci and c. trachomatis. such cross-reactions procure an inaccurate discrimination between the various chlamydia species which remains speculative anyhow when only a positive serological profile against one chlamydial subspecies is performed. we consider that using the serologic assay as proof for past sex ... | 1999 | 10413220 |
| activity of grepafloxacin and other fluoroquinones and newer macrolides against recent clinical isolates of chlamydia pneumoniae. | chlamydia pneumoniae is a frequent cause of community-acquired respiratory tract infection including pneumonia and bronchitis. quinolones have attracted interest as potential therapy for community-acquired respiratory tract infections because they are active against a wide range of pathogens including c. pneumoniae and mycoplasma pneumoniae. the in vitro susceptibilities of c. pneumoniae were determined for grepafloxacin, levofloxacin, moxifloxacin, trovafloxacin, clarithromycin and azithromycin ... | 1999 | 10418764 |
| genomic relatedness of chlamydia isolates determined by amplified fragment length polymorphism analysis. | the genomic relatedness of 19 chlamydia pneumoniae isolates (17 from respiratory origin and 2 from atherosclerotic origin), 21 chlamydia trachomatis isolates (all serovars from the human biovar, an isolate from the mouse biovar, and a porcine isolate), 6 chlamydia psittaci isolates (5 avian isolates and 1 feline isolate), and 1 chlamydia pecorum isolate was studied by analyzing genomic amplified fragment length polymorphism (aflp) fingerprints. the aflp procedure was adapted from a previously de ... | 1999 | 10419941 |
| demonstration of viable chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction. | the presence of chlamydia pneumoniae in atheromas has been demonstrated in several studies. culture of the organism from arterial tissue has been difficult. we report the use of a reverse transcriptase polymerase chain reaction to detect viable chlamydia pneumoniae in carotid atheromas. we analyzed 30 patients (14 females, mean age 69.6 +/- 8.8 years) who underwent surgery for the removal of atherosclerotic plaques from carotid arteries. during surgery, samples of lingual vein and superior thyro ... | 1999 | 10398739 |
| does persistent infection with chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure? | 1999 | 10400517 | |
| chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. | our identification of chlamydia pneumoniae in the cerebrospinal fluid (csf) of a patient with multiple sclerosis (ms) led us to examine the incidence of this organism in the csf from 17 patients with relapsing-remitting ms, 20 patients with progressive ms, and 27 patients with other neurological diseases (ond). csf samples were examined for c pneumoniae by culture, polymerase chain reaction assays, and csf immunoglobulin (ig) reactivity with c pneumoniae elementary body antigens. c pneumoniae wa ... | 1999 | 10401775 |
| epizootiology of chlamydia infections in two free-range koala populations. | the prevalence of chlamydia pecorum and chlamydia pneumoniae infections in two free-range koala populations was assessed using genus-specific pcr combined with species-specific dna probe hybridisation. population a had a very high overall level of chlamydial infection (85%) with significantly more of these infections being due to c. pecorum (73%) compared to c. pneumoniae (24%). the second population had a much lower prevalence of infection (10%) with equal levels of both species. an important f ... | 1999 | 10223324 |
| is streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? a microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. | although a wide variety of recognized pathogens can cause community-acquired pneumonia, in many patients the etiology remains unknown after routine diagnostic workup. the aim of this study was to identify the causal agent in these patients by obtaining lung aspirates with transthoracic needle aspiration. | 1999 | 10225239 |
| infectious agents that play a role in atherosclerosis and vasculopathies. what are they? what do we do about them? | much of the published data suggest a link between herpes infection and atherosclerosis, as well as herpes infection and restenosis. mechanistically, herpesvirus has been shown to promote inflammation, thrombin generation and platelet binding, and infected cells have been shown to be resistant to apoptosis. there is also good evidence of a link between chlamydia pneumoniae infection and atherosclerosis. in preliminary studies, antichlamydial antibiotic intervention has been shown to reduce signif ... | 1999 | 10350677 |
| value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. | we studied the causes of community-acquired pneumonia (cap) in 184 patients. microbiologic evaluation included sputum examination, blood culture, assessment of acute and convalescent antibody titers for legionella pneumophila, mycoplasma pneumoniae, chlamydia pneumoniae, coxiella psitacci, coxiella burnetii and respiratory viruses, polymerase chain reaction (pcr) assays for m. pneumoniae and c. pneumoniae in throat swab, and pcr assay based on the amplification of pneumolysin gene fragment in se ... | 1999 | 10351932 |
| relation between direct detection of chlamydia pneumoniae dna in human coronary arteries at postmortem examination and histological severity (stary grading) of associated atherosclerotic plaque. | numerous studies have suggested a link between chlamydia pneumoniae infection, atherosclerosis, and coronary artery disease. however, it is still unclear whether c pneumoniae plays a causal role in the pathogenesis of these conditions. accordingly, we have performed a systematic dissection of the 3 coronary arteries on 33 postmortem subjects and studied the relationship in individual artery segments between the presence of c pneumoniae dna and the severity of associated atherosclerosis. | 1999 | 10351965 |
| induction of hla class i-restricted cd8+ ctls specific for the major outer membrane protein of chlamydia trachomatis in human genital tract infections. | hla class i-restricted cd8+ ctls specific for the major outer membrane protein (momp) of chlamydia trachomatis are present in the peripheral blood of humans who acquired genital tract infections with the organism. three hla-a2-restricted epitopes and two hla-b51-restricted epitopes were identified in serovar e-momp. one of the five epitopes spans a variable segment of momp and is likely a serovar e-specific epitope. the other four epitopes are localized in constant segments and are c. trachomati ... | 1999 | 10352308 |
| chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein e-deficient mice. | accumulating evidence supports an association between chlamydia pneumoniae infection and atherosclerosis. to determine whether there is a causal relationship, the effects of chronic infection with c. pneumoniae on the development of atherosclerosis in apolipoprotein e (apoe)-deficient mice were evaluated. eight-week-old male apoe-deficient mice were inoculated intranasally with c. pneumoniae three times, at 8, 9, and 10 weeks of age. the combined area of atherosclerotic lesions in the lesser cur ... | 1999 | 10353889 |
| chlamydia pneumoniae-reactive t lymphocytes in abdominal aortic aneurysms: the smoking gun? | 1999 | 10354205 | |
| chlamydia pneumoniae reactive t lymphocytes in the walls of abdominal aortic aneurysms. | the presence of chlamydia pneumoniae in the walls of abdominal aortic aneurysms (aaas) has been demonstrated recently, but its role in the cause and/or maintenance of aortic wall inflammation is not known. in the present study, we have investigated the possible relationship between c. pneumoniae and the antigen specificity of t lymphocytes mediating inflammation in aaa tissue. | 1999 | 10354217 |
| immunoglobulin a antibodies against chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysm. | the aim of this study was to examine the possible association between the progression of small abdominal aortic aneurysm (aaa) and chronic infection with chlamydia pneumoniae. | 1999 | 10361184 |
| vascular surgical society of great britain and ireland: immunoglobulin a antibodies against chlamydia pneumoniae are associated with expansion of small abdominal aortic aneurysms and declining ankle blood pressure | background: the potential correlation between chronic infection with chlamydia pneumoniae and the progression of small abdominal aortic aneurysms (aaas) and lower limb atherosclerosis was studied. methods: mass screening for aaa was carried out in outdoor clinics at all hospitals in the county. some 139 men (aged 65-73 years) with a 3.0-4.9-cm aaa were followed prospectively for 1-3 (mean 2.7) years. initially, an interview and examination was performed, and blood samples were taken. results: so ... | 1999 | 10361204 |
| [chlamydia pneumoniae pneumonia. radiographic features in a patient with lung transplantation]. | 1999 | 10363065 | |
| chlamydia pneumoniae in a free-ranging giant barred frog (mixophyes iteratus) from australia. | the koala biovar of chlamydia pneumoniae was identified in lung tissue from a sick, free-ranging giant barred frog (mixophyes iteratus) by using electron microscopy, c. pneumoniae-specific fluorescent-antibody staining, cell culture, and sequencing of the ompa, ompb and 16s rrna genes. this is the first report of a chlamydial strain infecting both a homeotherm and a poikilotherm and only the fourth host (in addition to humans, koalas, and horses) to be naturally infected with this species of chl ... | 1999 | 10364623 |
| chlamydia trachomatis nucleic acids can be found in the synovium of some asymptomatic subjects. | the recent identification of antigens or nucleic acids of infectious agents in the joints of patients with reactive arthritis has raised questions about whether chlamydial or other infectious agent nucleic acids are also present in normal joints. we had the opportunity to study synovium from 30 asymptomatic volunteer subjects by use of polymerase chain reaction (pcr) for attempted identification of chlamydia and other infectious agents. | 1999 | 10366123 |
| antibiotics and heart disease. the story heats up. | 1999 | 10368527 | |
| chlamydia pneumoniae and coronary heart disease. | to review the potential association between chlamydia pneumoniae (cp) infection and coronary artery disease (cad), and to describe possible therapeutic interventions. | 1999 | 10369627 |
| chlamydia pneumoniae as a triggering infection in reactive arthritis. | to determine the role of chlamydia pneumoniae as a triggering infection in reactive arthritis (rea). | 1999 | 10371278 |
| in vitro hyperreactivity to lipopolysaccharide in patients with history of unstable angina is not associated with seropositivity for cytomegalovirus, helicobacter pylori and chlamydia pneumoniae. | inflammation and possibly chronic infections are associated with acute coronary syndromes; however, the mechanisms responsible for this association are not yet fully elucidated. the aim of this study was to assess whether the hyperreactivity of the inflammatory system, that we have shown in unstable patients with persistently elevated c-reactive protein and with recurrence of symptoms, was associated with chronic infection. | 1999 | 10371790 |
| azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome--a randomized study. | an open comparative study was undertaken in order to assess the efficacy and safety of a single dose of azithromycin in the treatment of community-acquired atypical pneumonia. a total of 100 adult patients with atypical pneumonia syndrome were randomized to receive 1.5 g of azithromycin as a single dose, or 500 mg once daily for 3 days. the presence of mycoplasma pneumoniae, chlamydia pneumoniae, chlamydia psittaci, coxiella burnetii, and legionella pneumophila infection was diagnosed by serolog ... | 1999 | 10378132 |
| evidence of 2 waves of chlamydia pneumoniae infection in gävle, sweden, 1990-96. | chlamydia pneumoniae is a common respiratory tract pathogen. the majority of adults have serological evidence of previous exposure. most infections are probably asymptomatic or subclinical. recent studies have implicated c. pneumoniae as a risk factor for the development of cardiovascular disease. it was therefore of interest to study new blood donors collected between the years of 1990 and 1996 for the purpose of delineating the epidemiological situation in the gävle area of sweden. sera from a ... | 1999 | 10381224 |